Table 1.
Characteristic of the studies for meta-analysis for MGMT methylation on LCs
| First author | Country | Ethnicity | Number of patients | Median age | Histology | Stage |
|---|---|---|---|---|---|---|
| Botana-Rial, 2012 | Spain | Caucasian | 30 | 63 | ADC | IV |
| Brabender, 2003 | U.S.A | Caucasian | 90 | 63 | 47.7% SCC, 35.6% ADC, 16.7% LCC | 49% I, 21% II, 30% IIIa |
| Buckingham, 2010 | U.S.A | Caucasian | 132 | 64 | 37.1% SCC, 47.7% ADC, 15.2% others | 61% I, 39% II |
| Drilon, 2014 | U.S.A | Caucasian | 107 | 68 | 18.7% SCC, 77.6% ADC, 3.7% LCC | 61.7% I, 25.2%II, 13.1% IIIa |
| Hashimoto, 2012 | Japan | Asian | 55 | 58 | 20.0% SCC, 72.7% ADC, 7.3% LCC | IV |
| Hoffmann, 2009 | Germany | Caucasian | 76 | 48 | 37% SCC, 47% ADC, 16% LCC | 17% I, 54% II, 29% IIIa |
| Pietanza, 2012 | U.S.A | Caucasian | 27 | 67 | SCLC | NR |
| Pulling, 2003 | U.S.A | Caucasian | 237 | 65 | ADC | 55.5% I, 21.6% II, 13.2% III, 9.7% IV |
| Safar, 2005 | U.S.A | Caucasian | 105 | 67 | NSCLC | 38% I, 8% II, 32% III, 22% IV |
SCC Squamous cell carcinoma, ADC Adenocarcinoma, LCC Large cell carcinoma.